Published in Cancer Weekly, February 3rd, 1997
"Hybrid" oligonucleotides are a class of antisense agents which have improved stability in vivo and are covered broadly in an allowed U.S. Patent application. The patent stems from a scientific collaboration between Hybridon's chief scientific officer, Dr. Sudhir Agrawal, University of Alabama at Birmingham (UAB), Dr. Robert Diasio, and Dr. Ruiwen Zhang, UAB.
The researchers published back-to-back...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.